A
Aspire Biopharma Holdings, Inc. (ASBP)
NCM – Real Time Price. Currency in USD
5.17
-0.35 (-6.34%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.17
-0.35 (-6.34%)
At close: May 12, 2026, 4:00 PM EDT
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
| Name | Position |
|---|---|
| Mr. Ernest J. Scheidemann Jr. | Chief Financial Officer |
| Mr. Kraig T. Higginson | Interim CEO, President & Executive Chairman of the Board |
| Mr. Stephen E. Quesenberry | General Counsel & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | DEF 14A | formdef14a.htm |
| 2026-04-27 | PRE 14A | formpre14a.htm |
| 2026-04-20 | 8-K | form8-k.htm |
| 2026-04-17 | 8-K/A | form8-ka.htm |
| 2026-04-16 | 8-K | form8-k.htm |
| 2026-04-15 | 8-K | form8-k.htm |
| 2026-04-10 | S-1/A | forms-1a.htm |
| 2026-04-08 | 10-K/A | form10-ka.htm |
| 2026-03-30 | 10-K | form10-k.htm |
| 2026-02-24 | DEF 14A | formdef14a.htm |